Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouché O, Monard L, Lambert A, Hammel P; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Conroy T, et al. Among authors: monard l. JAMA Oncol. 2022 Nov 1;8(11):1571-1578. doi: 10.1001/jamaoncol.2022.3829. JAMA Oncol. 2022. PMID: 36048453 Free PMC article. Clinical Trial.
Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies.
Edeline J, Hirano S, Bertaut A, Konishi M, Benabdelghani M, Uesaka K, Watelet J, Ohtsuka M, Hammel P, Kaneoka Y, Joly JP, Yamamoto M, Monard L, Ambo Y, Louvet C, Ando M, Malka D, Nagino M, Phelip JM, Ebata T. Edeline J, et al. Among authors: monard l. Eur J Cancer. 2022 Mar;164:80-87. doi: 10.1016/j.ejca.2022.01.009. Epub 2022 Feb 16. Eur J Cancer. 2022. PMID: 35182925
Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.
Nicolle R, Bachet JB, Harlé A, Iovanna J, Hammel P, Rebours V, Turpin A, Ben Abdelghani M, Wei A, Mitry E, Lopez A, Biagi J, François E, Artru P, Lambert A, Renouf DJ, Monard L, Mauduit M, Dusetti N, Conroy T, Cros J. Nicolle R, et al. Among authors: monard l. J Clin Oncol. 2024 Mar 20;42(9):1067-1076. doi: 10.1200/JCO.22.02668. Epub 2023 Nov 14. J Clin Oncol. 2024. PMID: 37963313 Free PMC article.
Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study.
Duffaud F, Italiano A, Bompas E, Rios M, Penel N, Mir O, Piperno-Neumann S, Chevreau C, Delcambre C, Bertucci F, Boudou-Rouquette P, Cancel M, Perrin C, Saada-Bouzid E, Monard L, Schiffler C, Chaigneau L, Hervieu A, Collard O, Bouvier C, Vidal V, Chabaud S, Blay JY; French Sarcoma Group. Duffaud F, et al. Among authors: monard l. Eur J Cancer. 2021 Jun;150:108-118. doi: 10.1016/j.ejca.2021.03.039. Epub 2021 Apr 22. Eur J Cancer. 2021. PMID: 33895682 Clinical Trial.
A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer.
Grosgeorges M, Picque Lasorsa L, Pastor B, Prévostel C, Crapez E, Sanchez C, Frayssinoux F, Jarlier M, Pezzella V, Monard L, Ychou M, Thierry AR, Mazard T, Blache P. Grosgeorges M, et al. Among authors: monard l. Sci Rep. 2023 Feb 15;13(1):2739. doi: 10.1038/s41598-023-29948-4. Sci Rep. 2023. PMID: 36792801 Free PMC article.
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study.
Duffaud F, Blay JY, Le Cesne A, Chevreau C, Boudou-Rouquette P, Kalbacher E, Penel N, Perrin C, Laurence V, Bompas E, Saada-Bouzid E, Delcambre C, Bertucci F, Cancel M, Schiffler C, Monard L, Bouvier C, Vidal V, Gaspar N, Chabaud S. Duffaud F, et al. Among authors: monard l. Br J Cancer. 2023 Dec;129(12):1940-1948. doi: 10.1038/s41416-023-02413-9. Epub 2023 Nov 1. Br J Cancer. 2023. PMID: 37914801 Clinical Trial.
Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?
Thebault E, Piperno-Neumann S, Tran D, Pacquement H, Marec-Berard P, Lervat C, Castex MP, Cleirec M, Bompas E, Vannier JP, Plantaz D, Saumet L, Verite C, Collard O, Pluchart C, Briandet C, Monard L, Brugieres L, Le Deley MC, Gaspar N. Thebault E, et al. Among authors: monard l. Cancers (Basel). 2021 Apr 2;13(7):1683. doi: 10.3390/cancers13071683. Cancers (Basel). 2021. PMID: 33918346 Free PMC article.